Three biologics targeting interleukin 5 (IL-5) or its receptor (IL-5Rα) are approved for use in patients with severe asthma. In a meta-analysis, Greek scientists have now investigated the clinical response to anti-IL-5/-5Rα biologics in real-world studies and provided insights into the use of these drugs in clinical practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Chronic pruritus: “Tour d'horizon”
Focus on new anti-inflammatory therapeutic approaches
- Multiple sclerosis
Unexpected side effects when switching from natalizumab to a biosimilar
- Immunotherapy
Subcutaneously or intravenously?
- Work-related asthma
When the job leads to exacerbations
- Inoperable NSCLC
Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy
- De-escalation strategies
De-escalation strategies – less is more
- Pain and autism
Hurdles to pain treatment for autistic patients
- Advanced NSCLC